SCHEDULE 13D/A: Major Shareholder Converts $20 Million Note, Boosting Stake to 48.1% in Elicio Therapeutics

Elicio Therapeutics, Inc. announced that GKCC, LLC, an entity controlled by board member Yekaterina Chudnovsky, converted a $20.3 million convertible note into 3,500,573 shares, increasing their beneficial ownership to 48.1% of the company's common stock.

Summary

• Elicio Therapeutics, Inc. filed an Amendment No. 5 to its Schedule 13D, detailing significant changes in beneficial ownership by GKCC, LLC and Yekaterina Chudnovsky.
• On August 12, 2024, Elicio Therapeutics issued a 3.0% Senior Secured Convertible Promissory Note with a principal amount of $20.0 million to GKCC, LLC.
• At the Annual Meeting on November 21, 2024, stockholders approved the Nasdaq Proposal, removing a 19.99% beneficial ownership limitation on shares from warrants and the convertible note.
• On March 5, 2025, the Convertible Note, with an outstanding balance of approximately $20.3 million (including accrued interest), was converted into 3,500,573 shares of Common Stock at a conversion price of $5.81 per share.
• Following the conversion, Yekaterina Chudnovsky beneficially owns 9,657,539 shares, representing approximately 48.1% of the outstanding Common Stock.
• GKCC, LLC beneficially owns 9,648,914 shares, representing approximately 48.0% of the outstanding Common Stock, with Ms. Chudnovsky having sole voting and investment control over these shares.
• The beneficial ownership calculation includes shares held directly, shares held by GKCC, and shares underlying Pre-Funded Warrants (2,632,702) and Common Warrants (1,600,000) exercisable within 60 days.

Sentiment

Score: 6

Explanation: The conversion of debt to equity is generally positive for a company's balance sheet, and increased insider ownership can signal confidence. However, the significant dilution and concentration of control (nearly 50% ownership by one party) introduce potential governance concerns and could be viewed negatively by some investors.

Positives

• Increased commitment and alignment from a significant insider (board member Yekaterina Chudnovsky) through a substantial equity stake.
• The conversion of debt to equity strengthens the company's balance sheet by reducing debt obligations.
• Shareholder approval of the Nasdaq Proposal indicates support for the transaction and the elimination of ownership limitations.

Negatives

• Significant dilution for existing shareholders due to the issuance of 3,500,573 new shares upon conversion of the note.
• Concentration of ownership: Yekaterina Chudnovsky and GKCC, LLC now control approximately 48.1% of the company, potentially impacting corporate governance and control.

Risks

• Share Dilution: The conversion of the convertible note into 3,500,573 shares of Common Stock significantly dilutes the ownership percentage of existing shareholders.
• Concentration of Control: The beneficial ownership of approximately 48.1% by Yekaterina Chudnovsky and GKCC, LLC could lead to a high degree of control over company decisions, potentially limiting influence from other shareholders.

Future Outlook

The document primarily details a past transaction and current ownership structure, with no explicit forward-looking statements or guidance regarding future company performance or strategic direction beyond the completion of the note conversion.

Industry Context

This filing is specific to an ownership change within Elicio Therapeutics, Inc. and does not provide broader industry trends or competitive analysis. The conversion of a convertible note is a common financing mechanism, but the significant increase in a single insider's stake to nearly 50% is a company-specific event.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The issuance of the $20.0 million 3.0% Senior Secured Convertible Promissory Note to GKCC, LLC on August 12, 2024, is a related party transaction, as GKCC, LLC is an entity controlled by Yekaterina Chudnovsky, a member of the Issuer's board of directors.
• The subsequent conversion of this note into 3,500,573 shares of Common Stock on March 5, 2025, is also part of this related party transaction.

Stakeholder Impact

• Shareholders: Experience significant dilution due to the issuance of new shares, but also benefit from the conversion of debt to equity, which strengthens the company's balance sheet. The increased concentration of ownership by a single party may impact voting power and influence.
• Creditors: The conversion of the convertible note reduces the company's debt obligations, potentially improving its credit profile.

Next Steps

• The document does not explicitly mention future actions, events, or milestones beyond the completed conversion of the note.

Key Dates

Keywords

Elicio Therapeutics, ELTX, Schedule 13D, Beneficial Ownership, Convertible Note, Debt Conversion, Share Dilution, GKCC LLC, Yekaterina Chudnovsky, SEC Filing, Corporate Governance, Nasdaq Listing Rule 5635(b), Warrants